Watch a series of internationally ophthalmology specialists from Europe discuss the latest key clinical data from EURETINA 2019, in Paris, France, 5–8 September 2019.
The potential implications of these data for optimizing clinical outcomes for patients with nAMD are explored from both global and regional perspectives.
The information in this activity is intended for retina specialists and other healthcare professionals involved in the treatment of patients with nAMD.
After watching these touchCONGRESS Expert Interviews from EURETINA 2019, you should be able to:
- Illustrate how retinal fluid may be used as a marker of disease activity and to guide individualized therapeutic strategy
- Define the importance of patient adherence to treatment on clinical outcomes and the factors that impact adherence and QoL
- Explain how smaller sized anti-VEGF antibodies may address the real-life unmet needs and confer clinical benefits